1 / 8

ELISA II Trial

ELISA II Trial. ELISA II Trial. Presented at The European Society of Cardiology Hot Line Session 2005 Presented by Dr. Saman Rasoul. ELISA II Trial.

sawyer-avery
Download Presentation

ELISA II Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ELISA II Trial ELISA II Trial Presented at The European Society of Cardiology Hot Line Session 2005 Presented by Dr. Saman Rasoul

  2. ELISA II Trial 328 patients with non-ST elevation MI; ischemic chest pain at rest within 24 hrs; and either positive biomarkers (CKMB or troponin) or an abnormal ECG (ST depression >0.1 mV in >2 leads or transient ST elevation) 29% female, mean age 63 years, mean follow-up 30 days Low-molecular weight heparin, beta-blocker, and statin therapy were administered to all patients Triple anti-platelet strategy with aspirin, standard-dose clopidogrel (300mg load), and tirofiban (10 μg/kg bolus followed by 0.15 μg/kg infusion) n=162 Dual anti-platelet strategy with aspirin and high-dose clopidogrel (600 mg load) n=166 Angiography with or without revascularization (24-48 hrs) • Primary Endpoint: Infarct size as assessed by LDHQ at 48 hours and as assessed by peak CK • Secondary Endpoint: Initial TIMI flow grade of the culprit artery Presented at ESC 2005

  3. ELISA II Trial: Baseline Characteristics Median time to angiography • In the dual therapy group, median time to angiography was 26 hours. In the triple therapy group, median time to angiography was 30 hrs. • 81% of enrolled patients had a positive troponin and 62% had ST depression • PCI was performed in ~60% of patients Presented at ESC 2005

  4. ELISA II Trial: Primary Endpoint Analysis of infarct size when assessed by LDHQ p=0.36 • The primary endpoint of infarct size did not differ between the dual therapy group and the triple therapy group when assessed by LDHQ (p=0.36) or peak CK (p=NS) 392 331 Presented at ESC 2005

  5. ELISA II Trial: Secondary Endpoint Analysis of initial TIMI grade 3 flow at angiography (%) p=0.002 • The secondary endpoint of initial TIMI grade 3 flow at angiography was higher in the triple therapy group (47% vs 67%) Presented at ESC 2005

  6. ELISA II Trial: MI Free Survival at 30 days Analysis of survival free from myocardial infarction at 30 days (%) p=0.098 • A trend toward higher rates of survival free from myocardial infarction at 30 days were observed in the triple therapy group • These results were driven almost exclusively by myocardial infarction (56% MI rate in the dual therapy group vs 46% MI rate in the triple therapy group) • Mortality rate of 1% in each group Presented at ESC 2005

  7. ELISA II Trial: Bleeding Analysis of bleeding (%) p = NS • No significant difference among bleeding existed between the two treatment groups • There were no strokes in either of the two treatment groups Presented at ESC 2005

  8. ELISA II Trial Summary • Among patients with non-ST elevation MI undergoing angiography with or without revascularization, use of a triple anti-platelet regimen of aspirin, 300mg clopidogrel, and tirofiban was not associated with a difference in the primary endpoint of enzymatic infarct size compared with a dual anti-platelet regimen of aspirin and a 600 mg loading dose of clopidogrel. • The secondary endpoint of TIMI grade 3 flow was improved among the triple therapy treatment group. • A favorable trend toward lower rates of MI through 30 days was observed in the triple therapy group. • Further investigation of the clinical benefit of triple therapy is warranted (upcoming ISAR-REACT 2). Presented at ESC 2005

More Related